MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / News Well / Medtronic misses efficacy endpoint in Symplicity renal denervation trial

Medtronic misses efficacy endpoint in Symplicity renal denervation trial

January 9, 2014 By Brad Perriello Leave a Comment

YYmeta

Medtronic (NYSE:MDT) said its Symplicty renal denervation device failed to meet the efficacy endpoint in a U.S. pivotal trial, Symplicity HTN-3, prompting it to suspend enrollment in its other Symplicity trials around the world and to say that a writedown of its renal denervation assets is likely.

"Symplicity HTN-3 met its primary safety endpoint related to the incidence of major adverse events one month following randomization and renal artery stenosis to six months," co-principal investigator Dr. Deepak Bhatt, of Boston’s Brigham & Women’s Hospital, said in prepared remarks. "Importantly, however, the trial did not meet its primary efficacy endpoint."

"While it’s disappointing the trial did not meet its primary efficacy endpoint, this is the most rigorous renal denervation clinical trial conducted to date, and the first of its kind to include a sham-control group. We look forward to advancing these data into the peer-review process and will submit these findings for presentation and scientific discussion at an upcoming scientific congress," added co-principal investigator Dr. George Bakris of the University of Chicago Medicine.

Medtronic said it will assemble an independent panel to recommend next steps for its global hypertension program, "as well as provide advice on continued physician and patient access to the Symplicity technology in countries with regulatory approvals," according to a press release.

Enrollment in 3 other renal denervation trials – Symplicity HTN-4 in the U.S., HTN-Japan and HTN-India – will be suspended while the Fridley, Minn.-based medtech titan informs patients and physicians of the Symplicity HTN-3 results. Medtronic will still sell the Symplicity device in markets where it’s already won approval, according to the release. Post-market registry studies and trials investigating indications other than high blood pressure will continue, Medtronic said.

"We are disappointed that the clinical trial failed to meet its primary efficacy endpoint," chief medical officer Dr. Rick Kuntz said in prepared remarks. "We believe this course of action is the most prudent and will help us thoroughly evaluate these findings and determine the appropriate next steps for renal denervation therapy. We would like to thank the patients and investigators for their participation in the trial and their important contribution to the field of hypertension research."

Medtronic reiterated its outlook for fiscal 2014 for earnings per share of $3.80 – $3.85 on sales growth of 3% to 4% and adjusted EPS growth of 6% to 8%.

The implications of the Symplicity HTN-3 outcome are unclear for St. Jude Medical (NYSE:STJ), which called off the Enlightn IV trial of the next generation of its renal denervation technology last month, just a few months after it began. The trial of St. Jude’s multi-electrode Enlightn device was slated to enroll about 590 patients between the ages of 18 and 80 with high blood pressure that isn’t well-managed with drugs.

But concerns that Medtronic’s Symplicity device could reach the U.S. market led St. Jude to spike the Enlightn IV trial, which it launched in May. Having another technology on the market would make it tough to interest patients in the trial, which might see them enrolled in the sham arm of the study, a company spokeswoman told MassDevice.com at the time.

St. Jude did not immediately respond to a request for comment.

Filed Under: News Well Tagged With: Clinical Trials, Hypertension, Minnesota, stjudemedical

In case you missed it

  • Bio-Rad recovering from ransomware attack
  • FDA clears first single-use duodenoscope from Boston Sci
  • FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller
  • Awak Technologies raises $40m
  • Axonics raises additional $17m in public offering
  • Siemens Healthineers lands FDA clearance for two CT systems
  • Aethlon prices $5m offering
  • Sterigenics’ legal troubles mount in Illinois
  • In2Bones launches AlloAid BioNail
  • Caresyntax to acquire Syus; raises $45.6m
  • Nihon Kohden launches new patient monitor
  • Senate confirms Dr. Stephen Hahn to lead FDA
  • Iradimed renews CE mark for MRI-safe patient monitor
  • Flexicare recalls fiber optic laryngoscope blades and handles
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • TransEnterix announces reverse split of common stock
  • GI Windows raises $15m Series A

RSS From Medical Design & Outsourcing

  • Siemens Healthineers lands FDA clearance for two CT systems
    Siemens Healthineers this week said it won FDA clearance for its Somatom go.Sim and Somtom go.Open Pro computed tomography systems. The CT systems are designed for radiation therapy planning and are members of the company’s Somatom go. platform of devices. Siemens Healthineers’ platform uses hardware and software components like patient marking lasers and automated quality… […]
  • Protolabs’ healthcare grant spurs 2 feeding tube inventions
    Digital manufacturer Protolabs (NYSE:PRLB) announced today that MedStar Health (Columbia, Md.) and Cleveland Clinic Innovations are joint winners of the company’s Cool Idea Award: Healthcare Grant. These grants provide in-kind manufacturing services to the support development of medical products to spur innovation in the field. MedStar Health’s gravity-feed syringe holder simplifies the feeding of newborns who spend […]
  • Sterigenics’ legal troubles mount in Illinois
    Nearly two dozen new lawsuits were filed against Sterigenics this week over its now-shuttered ethylene oxide (EtO) sterilization plant in Willowbrook, Ill., according to a law firm representing some of the plaintiffs. That brings the total of such lawsuits to nearly 75, noted Chicago personal injury lawyer Antonio Romanucci, court-appointed lead counsel from among five… […]
  • In2Bones launches AlloAid BioNail
    In2Bones this week launched its AlloAid BioNail sterile allograft implant. The implant is designed to give rigid, stable fixation during hand and foot reconstruction. AlloAid BioNail is made from strong cortical allografts to provide osteoconductive properties for bone remodeling and healing. It features a tapered point and multiple, contoured wedge facets to ease insertion, anchor… […]
  • Protolabs’ healthcare grant spurs 2 feeding tube inventions
    Digital manufacturer Protolabs (NYSE:PRLB) announced today that MedStar Health (Columbia, Md.) and Cleveland Clinic Innovations are joint winners of the company’s Cool Idea Award: Healthcare Grant. These grants provide in-kind manufacturing services to the support development of medical products to spur innovation in the field. MedStar Health’s gravity-feed syringe holder simplifies the feeding of newborns… […]
  • Nihon Kohden launches new patient monitor
    Nihon Kohden (TYO:6849) announced the U.S. launch of its Life Scope SVM-7200 series vital signs monitor for outpatient facilities and beds that aren’t continuously monitored. The Life Scope SVM-7200 is designed to provide customizable early warning scoring to help clinicians identify patients who are deteriorating or at risk of deterioration. It combines vital signs data with… […]
  • Senate confirms Dr. Stephen Hahn to lead FDA
    The U.S. Senate has confirmed Dr. Stephen Hahn as the next commissioner of the FDA. The vote was 72 to 18, according to a report in the New York Times. Hahn will be the first permanent commissioner of the agency since Dr. Scott Gottlieb resigned in April. President Trump nominated Hahn, the chief medical officer at Houston’s… […]
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
    3M (NYSE:MMM) announced today that it entered into an agreement to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. St. Paul, Minn.-based 3M will retain its transdermal drug delivery components business, according to a news release. The business being divested has annual global sales reaching approximately… […]
  • Lawsuit endangers Sterigenics consent order in Georgia
    A consent order that Sterigenics entered into with the state of Georgia to reduce ethylene oxide (EtO) emissions at its Atlanta medtech sterilization plant may be in jeopardy. A hearing is scheduled today on a lawsuit that accuses the Georgia Environmental Protection Division (EPD) of failing to take public comment before entering the Aug. 7… […]
  • Trelleborg acquires Tritec Seal
    Trelleborg Sealing Solutions said today it has closed on its acquisition of rotary seal manufacturer Tritec Seal, which produces engineered polytetrafluoroethylene (PTFE) sealing solutions. Trelleborg said the acquisition strengthens its product portfolio while giving the business area access to increased manufacturing capacity. Headquartered in Fenton, Mich., with additional manufacturing in Giddings, Texas, Tritec Seal generated… […]
  • RSNA 2019: 7 radiology innovations you need to know
    Nearly 53,000 people attended the 2019 Radiological Society of North America annual meeting in Chicago last week. And they heard the same acronym over and over again: AI. Exhibitors at the conference touted their artificial-intelligence-enhanced technology at every turn, claiming to make images clearer, sharper, easier to use and powerful enough to help clinicians make… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS